A-gene pharm

AgenePharm is a clinical-stage biotechnology company based in South Korea, focused on developing next-generation RNA interference (RNAi) therapeutics. The company is a subsidiary of Bioneer Corporation and leverages the proprietary SAMiRNA (Self-Assembled Micelle RNAi) platform, which enables the stable and targeted delivery of siRNA to diseased tissues without the need for complex lipid nanoparticles. AgenePharm's lead program, SRN-001, is a first-in-class siRNA therapeutic targeting TGF-beta 1 for the treatment of idiopathic pulmonary fibrosis and keloids. The company is also expanding its pipeline into oncology, targeting growth factors like amphiregulin to treat various solid tumors.